AMERSHAM, United Kingdom, Jan. 28 / PRNewswire /) –
- From the location selection in the Guangzhou Biopark to the handover in the midst of the global pandemic, the 17,000 square meter site was completed in less than two years
- From Lonza’s first biologics manufacturing facility in China, the leading healthcare provider will provide the manufacturing solutions and services needed to meet growing global drug needs
- The site is set to become a strategic base in China for Lonza to provide CDMO services across the Asia-Pacific region
Cytiva, a global leader in life sciences, has successfully completed another KUBio installation, this time for global healthcare solutions provider Lonza in Biopark Guangzhou, China. The modular high-throughput bioproduction facility provides process development and manufacturing solutions for Chinese companies developing innovative drugs as well as multinational companies wishing to manufacture in China.
The 17,000 square meter site includes 6,500 square meters of laboratory space and a modular KUBio facility and enables the rapid start-up of development services and the production of antibodies that are urgently needed to meet the market needs for biologics, including monoclonal antibodies (MAbs) and other complexes Proteins to respond in and for China and the rest of the world.
The growth of the Chinese biologics sector has outpaced global growth, especially in recent years. It is estimated that the biologics market in China has grown from just under USD 10 billion in 2012 to over USD 45 billion in 2020
Stefan Stoffel, Lonza’s Chief Operating Officer, said: “The Cytiva team showed great flexibility and speed in providing this significant location. With the now operational single-use platform KUBio and FlexFactory, Lonza can respond to the high demand for innovative therapies now and in the future react to the current environment. “
Olivier Loeillot, Vice President of Cytiva stated, “In a rapidly growing industry with increasing demand for monoclonal antibodies (MAbs) and other major biopharmaceuticals, this facility shows the strength of combining modular manufacturing with single-use technologies. Together, KUBio and FlexFactory are accelerating the delivery of innovations Therapeutics for patients. “
On the grounds of the Guangzhou Biopark, the construction and delivery of building materials have sometimes been subject to lockdown and travel restrictions due to the COVID-19 pandemic. Nevertheless, the entire project was completed within the planned time frame.
This is Lonza’s first biologics facility in China. Lonza will combine Cytiva’s modular KUBio system with single-use equipment to ensure manufacturing in accordance with GMP (Good Manufacturing Practice) guidelines, which are followed in its own platforms and in development, including cell line and process development . Thanks to the flexibility in design, production scaling is optimized if necessary.
Guangzhou Biopark is also home to manufacturing facilities for BeiGene and Akesobio, for which Cytiva has also provided solutions. Cytiva has delivered 77 KUBio and FlexFactory solutions to customers worldwide.
More information: More Information about KUBio Animation of the Lonza construction site in Guangzhou Video About the Cytiva solution for BeiGene Read the prior notice with
Information on Cytiva
Cytiva is a global leader in the life sciences with more than 7,000 employees in 40 countries who are committed to the advancement and increased production speed of therapeutics. As a trusted partner for customers of all sizes, Cytiva guarantees speed, efficiency and capacity in research and manufacturing processes, enabling the development, manufacture and supply of transformative drugs
for patient treatment.
Inquiries & contact:
email@example.com OR Colleen Connolly in the US